课题基金 / 基金详情

Development of Analytical Tests for Detection of Pathogenicity and Identification of Molecular Defects in Unclear Genetic Variants of the DNA Mismatch Repair Gene MSH2 in Lynch Syndrome

Development of Analytical Tests for Detection of Pathogenicity and Identification of Molecular Defects in Unclear Genetic Variants of the DNA Mismatch Repair Gene MSH2 in Lynch Syndrome
林奇综合征 DNA 错配修复基因 MSH2 不清楚的遗传变异的致病性检测和分子缺陷鉴定分析测试的开发
批准号:
270558391
负责人:
Privatdozent Dr. Guido Plotz
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
2015
资助国家:
德国
项目状态:
已结题
起止时间:
2014-12-31 至 2020-12-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
MSH2基因的失活突变导致林奇综合征,这是一种可遗传的癌症易感性。在患者中鉴定MSH2中的失活突变能够在家庭成员中进行预测性诊断和靶向癌症监测。然而,在很大一部分MSH2变体中,尚不清楚它们是否失活并因此致病。这些“不确定意义的变体”(VUS)需要分类,以建立诊断。在大多数情况下,这种分类需要在实验室中对变体MSH2基因或蛋白进行功能分析。然而,目前还没有包含循证参考限值或分类器的功能性检测,可以将检测结果转化为致病性声明。在该项目中,计划分析在癌症患者中鉴定的遗传MSH2变体。将这些变体引入MSH2表达载体中,并在细胞培养物中或体外表达。然后进行功能分析,包括(例如):表达水平(RNA和蛋白质)、蛋白质稳定性、催化活性、亚细胞定位、与蛋白质伴侣的相互作用等。除VUS外,还纳入了已知临床状态(致病性或中性)的变体作为对照,以建立参考限值或确定测定的分类器。这将允许将VUS的功能结果转化为适用于临床诊断的致病性陈述。在建立用于临床应用的测试系统的同时,在不同变体中鉴定的分子缺陷将用于指导对MSH2蛋白功能的深入分析,包括其蛋白质相互作用表面、DNA结合模式和ATP酶循环。
英文摘要
Inactivating mutations of the MSH2 gene cause Lynch syndrome, a heritable cancer predisposition. Identification of an inactivating mutation in MSH2 in a patient enables predictive diagnosis and targeted cancer surveillance in family members. However, in a significant portion of MSH2 variants it is unclear if they are inactivating and therefore pathogenic. These "variants of uncertain significance" (VUS) need to be classified in order to establish a diagnosis. In most cases, this classification requires a functional analyses of the variant MSH2 gene or protein in the laboratory. However, currently there are no functional tests available which comprise evidence-based reference limits or classifiers that allow translating the test result into a pathogenicity statement. In this project, it is planned to analyze genetic MSH2 variants identified in cancer patients. These variants are introduced into MSH2 expression vectors and are expressed in cell culture or in vitro. Functional analyses are then performed and comprise (for example): expression level (RNA and protein), protein stability, catalytic activity, subcellular localization, interaction with protein partners and others. Besides VUS, variants with known clinical status (pathogenic or neutral) are included as controls to establish reference limits or identify classifiers for the assays. This will allow to translate functional results of the VUS into pathogenicity statements suitable for use in clinical diagnosis.In parallel to establishing test systems for clinical applications, the molecular defects identified in the different variants will serve to guide a thourough analysis of the MSH2 protein functions, including its protein interaction surfaces, DNA binding modes and ATPase cycle.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1002/gcc.22536
发表时间: 2018-07-01
期刊: GENES CHROMOSOMES & CANCER
影响因子: 3.7
作者: [Koeger, Nicole, Paulsen, Lea, Plotz, Guido]
通讯作者: Plotz, Guido
DOI: 10.1002/humu.23709
发表时间: 2019-04-01
期刊: HUMAN MUTATION
影响因子: 3.9
作者: [Koeger, Nicole, Brieger, Angela, Plotz, Guido]
通讯作者: Plotz, Guido
国内基金
海外基金
Galaxy Analytical Modeling Evolution (GAME) and cosmological hydrodynamic simulations.
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    Antonios Katsianis
  • 依托单位: